Clinical trials: Neoplasms, Oral
Oral Cavity Squamous Cell Carcinoma, Saliva Altered
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
According to the World Health Organization, oral cancer (OC) is the eighth most common cancer in the world with a five year survival rate of 50%.
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Saliva Altered, Precancerous Lesions
- Trial name
- OCSALTM (NCT03529604)
- Testing
- Saliva sampling, ELISA, HPLC
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Zagreb
Advanced Cancer, Non-Small Cell Lung Cancer
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
To determine the toxicities, maximum tolerated dose (MTD) and recommended phase 2 dose of MKC-1 when administered orally, twice daily for 14 days followed by 7 days without dosing, in combination with pemetrexed (delivered at its…
- Trial name
- NCT00408226
- Testing
- MKC-1, pemetrexed
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus…
- Trial name
- NCT03397706
- Testing
- VRx-3996 and valganciclovir
- Where
- 28 sites in United States, Brazil
- Volunteers
- 64 people
- Sponsor
- Viracta Therapeutics, Inc.
Cancer, Hematologic Malignancies
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
This study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The dose escalation part of the study is aimed at evaluating the safety, tolerability and PK (pharmacokinetics) of oral AMG 900 in subjects…
- Conditions
- Cancer, Hematologic Malignancies, Leukemia, Myeloid Leukemia
- Trial name
- NCT01380756
- Testing
- Arm 1- Dose Escalation, Arm 2- Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Amgen
Cancer of the Tongue
Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL
In terms of incidence, cancer of the tongue is one of the leading cancers in France. Moreover, this cancer is associated with physiological complications ranging from swallowing disorders to loss of taste.
- Trial name
- NCT03305302
- Testing
- Sample of cancerous epithelium from the tongue
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Multiple Myeloma
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.
- Trial name
- NCT03748953
- Testing
- Ixazomib
- Where
- 10 sites in China
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer of Head and Neck, Cancer
Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients
The purpose of this study is to determine whether continuous use of edible, gel-based artificial saliva in cancer patients with dry mouth problems will reduce signs and symptoms of dry mouth and improve quality of patients'…
- Conditions
- Cancer of Head and Neck, Cancer, Radiation-induced Xerostomia, Dry Mouth
- Trial name
- NCT01885065
- Testing
- Gel-based artificial saliva
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Dental Innovation Foundation Under Royal Patronage
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
This is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy.
- Conditions
- Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- Rambro2 (NCT05980000)
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
Human Papillomavirus Infection, Human Immunodeficiency Virus Infection
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
The goal of this observational study is to estimate the prevalence of HPV infections anal and ENT level and according to HIV status in transgender (TG) population.
- Conditions
- Human Papillomavirus Infection, Human Immunodeficiency Virus Infection, Sexually Transmitted Diseases
- Trial name
- PrevHPV-TG (NCT05981807)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Antibiotic, Bowel Cancer
Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery
Investigation of the role of adding oral antibiotics to preoperative mechanical bowel preparation before colorectal surgery for cancer.
- Conditions
- Antibiotic, Bowel Cancer, Colorectal Cancer, Surgical Site Infection
- Trial name
- MECCA (NCT03563586)
- Testing
- Bowel Preparation plus antibiotics, Bowel Preparation
- Where
- Greece
- Volunteers
- 210 people
- Sponsor
- National and Kapodistrian University of Athens
Prostate Cancer
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.
- Trial name
- NCT01483586
- Testing
- kanglaite gelcap
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- KangLaiTe USA
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Prostate Cancer
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer.
- Trial name
- NCT00151086
- Testing
- Estramustine, Vinorelbine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Michigan Rogel Cancer Center
Ischemic Stroke, Acute
Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes
This randomized, double-blind, placebo-controlled trial aims to evaluate the effect of oral DLBS1033 as adjunctive therapy on inflammatory biomarkers (IL-6, TNF-α, MMP-9, D-dimer), transcranial Doppler (TCD) parameters, and…
- Trial name
- NCT07121569
- Testing
- Oral lumbrokinase DLBS1033
- Where
- Indonesia
- Volunteers
- 52 people
- Sponsor
- Universitas Sebelas Maret
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT01279473
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis…
- Trial name
- BLOOM (NCT02228369)
- Testing
- AZD3759, AZD9291
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Taste, Altered, Xerostomia
An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer
Taste problems and xerostomia (dry mouth) are common among patients with advanced cancer. These symptoms can affect the pleasure of eating and drinking, reduce dietary intake, cause low mood, and a lower quality of life.
- Conditions
- Taste, Altered, Xerostomia, Neoplasms
- Trial name
- NCT06287294
- Where
- Ireland
- Volunteers
- 120 people
- Sponsor
- Our Lady's Hospice and Care Services
HNSCC, SCC - Squamous Cell Carcinoma
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled…
- Conditions
- HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
- Trial name
- NCT07741565
- Testing
- Nivolumab-IRDye800
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.